# Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

> **NCT03707808** · PHASE1,PHASE2 · RECRUITING · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 18 (estimated)

## Conditions studied

- Solid Tumor
- Metastases to Soft Tissue

## Interventions

- **DRUG:** intratumoral injection of autologous CD1c (BDCA-1)+ myDC
- **DRUG:** Intratumoral injection of ipilimumab and AS01b
- **DRUG:** IV nivolumab

## Key facts

- **NCT ID:** NCT03707808
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-29
- **Primary completion:** 2025-12-24
- **Final completion:** 2025-12-24
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707808, "Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03707808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*